|
1
|
Borowitz MJ, Chan JKC, Béné M and Arber
DA: T-lymphoblastic leukemia/lymphoma. WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th
edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA,
Stein H and Thiele J: The International Agency for Research on
Cancer; Lyon: pp. 209–213. 2017
|
|
2
|
Czader M, Molina TJ, Choi JK, Leventaki V,
Miles RR, Lin P, Saha V, Tembhare P and Chandy M: T-lymphoblastic
leukaemia/lymphoma NOS. WHO Classification of Tumours Editorial
Board: Haematolymphoid tumours [Internet; beta version ahead of
print]. 11:5th edition. International Agency for Research on
Cancer; Lyon: 2022, https://tumourclassification.iarc.who.int/chapters/63.
Accessed January 17, 2023
|
|
3
|
Tan TK, Zhang C and Sanda T: Oncogenic
transcriptional program driven by TAL1 in T-cell acute
lymphoblastic leukemia. Int J Hematol. 109:5–17. 2019. View Article : Google Scholar
|
|
4
|
Bardelli V, Arniani S, Pierini V, Di
Giacomo D, Pierini T, Gorello P, Mecucci C and La Starza R: T-cell
acute lymphoblastic leukemia: Biomarkers and their clinical
usefulness. Genes (Basel). 12:11182021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferrando AA, Neuberg DS, Staunton J, Loh
ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland
DG, et al: Gene expression signatures define novel oncogenic
pathways in T cell acute lymphoblastic leukemia. Cancer Cell.
1:75–87. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu Y, Easton J, Shao Y, Maciaszek J, Wang
Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, et al:
The genomic landscape of pediatric and young adult T-lineage acute
lymphoblastic leukemia. Nat Genet. 49:1211–1218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Begley CG, Aplan PD, Davey MP, Nakahara K,
Tchorz K, Kurtzberg J, Hershfield MS, Haynes BF, Cohen DI, Waldmann
TA, et al: Chromosomal translocation in a human leukemic stem-cell
line disrupts the T-cell antigen receptor delta-chain diversity
region and results in a previously unreported fusion transcript.
Proc Natl Acad Sci USA. 86:2031–2035. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aplan PD, Jones CA, Chervinsky DS, Zhao X,
Ellsworth M, Wu C, McGuire EA and Gross KW: An scl gene product
lacking the transactivation domain induces bony abnormalities and
cooperates with LMO1 to generate T-cell malignancies in transgenic
mice. EMBO J. 16:2408–2419. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tremblay M, Tremblay CS, Herblot S, Aplan
PD, Hébert J, Perreault C and Hoang T: Modeling T-cell acute
lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes
Dev. 24:1093–1105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grabher C, von Boehmer H and Look AT:
Notch 1 activation in the molecular pathogenesis of T-cell acute
lymphoblastic leukaemia. Nat Rev Cancer. 6:347–359. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu
K and Chu Q: Notch signaling pathway: Architecture, disease, and
therapeutics. Signal Transduct Target Ther. 7:952022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wolfe MS, Xia W, Ostaszewski BL, Diehl TS,
Kimberly WT and Selkoe DJ: Two transmembrane aspartates in
presenilin-1 required for presenilin endoproteolysis and
gamma-secretase activity. Nature. 398:513–517. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levitan D, Lee J, Song L, Manning R, Wong
G, Parker E and Zhang L: PS1 N- and C-terminal fragments form a
complex that functions in APP processing and Notch signaling. Proc
Natl Acad Sci USA. 98:12186–12190. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Güner G and Lichtenthaler SF: The
substrate repertoire of γ-secretase/presenilin. Semin Cell Dev
Biol. 105:27–42. 2020. View Article : Google Scholar
|
|
15
|
Steinbuck MP and Winandy S: A review of
Notch processing with new insights into ligand-independent Notch
signaling in T-cells. Front Immunol. 9:12302018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hosokawa H and Rothenberg EV: How
transcription factors drive choice of the T cell fate. Nat Rev
Immunol. 21:162–176. 2021. View Article : Google Scholar
|
|
17
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sulis ML, Williams O, Palomero T, Tosello
V, Pallikuppam S, Real PJ, Barnes K, Zuurbier L, Meijerink JP and
Ferrando AA: NOTCH1 extracellular juxtamembrane expansion mutations
in T-ALL. Blood. 112:733–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrando AA: The role of NOTCH1 signaling
in T-ALL. Hematology Am Soc Hematol Educ Program. 353–361. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ashworth TD, Pear WS, Chiang MY, Blacklow
SC, Mastio J, Xu L, Kelliher M, Kastner P, Chan S and Aster JC:
Deletion-based mechanisms of Notch1 activation in T-ALL: Key roles
for RAG recombinase and a conserved internal translational start
site in Notch1. Blood. 116:5455–5464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Real PJ, Tosello V, Palomero T, Castillo
M, Hernando E, de Stanchina E, Sulis ML, Barnes K, Sawai C,
Homminga I, et al: Gamma-secretase inhibitors reverse
glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Nat Med. 15:50–58. 2009. View Article : Google Scholar
|
|
22
|
López-Nieva P, González-Sánchez L,
Cobos-Fernández MÁ, Córdoba R, Santos J and Fernández-Piqueras J:
More insights on the use of γ-secretase inhibitors in cancer
treatment. Oncologist. 26:e298–e305. 2021. View Article : Google Scholar
|
|
23
|
Baratta MG: Adjusting the focus on
γ-secretase inhibition. Nat Rev Cancer. 19:4192019. View Article : Google Scholar
|
|
24
|
Habets RA, De Bock CE, Serneels L,
Lodewijckx I, Verbeke D, Nittner D, Narlawar R, Demeyer S, Dooley
J, Liston A, et al: Safe targeting of T cell acute lymphoblastic
leukemia by pathology-specific NOTCH inhibition. Sci Transl Med.
11:eaau62462019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Palomero T, Sulis ML, Cortina M, Real PJ,
Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, et
al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition
in T-cell leukemia. Nat Med. 13:1203–1210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martelli AM, Paganelli F, Fazio A,
Bazzichetto C, Conciatori F and McCubrey JA: The key roles of PTEN
in T-cell acute lymphoblastic leukemia development, progression,
and therapeutic response. Cancers (Basel). 11:6292019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gills JJ, Lopiccolo J, Tsurutani J,
Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner
ER, Danish M, et al: Nelfinavir, A lead HIV protease inhibitor, is
a broad-spectrum, anticancer agent that induces endoplasmic
reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Clin Cancer Res. 13:5183–5194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blumenthal GM, Gills JJ, Ballas MS,
Bernstein WB, Komiya T, Dechowdhury R, Morrow B, Root H, Chun G,
Helsabeck C, et al: A phase I trial of the HIV protease inhibitor
nelfinavir in adults with solid tumors. Oncotarget. 5:8161–8172.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawabata S, Connis N, Gills JJ, Hann CL
and Dennis PA: Nelfinavir inhibits the growth of small-cell lung
cancer cells and patient-derived xenograft tumors. Anticancer Res.
41:91–99. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Subeha MR and Telleria CM: The anti-cancer
properties of the HIV protease inhibitor Nelfinavir. Cancers
(Basel). 12:34372020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eder J, Hommel U, Cumin F, Martoglio B and
Gerhartz B: Aspartic proteases in drug discovery. Curr Pharm Des.
13:271–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lobbardi R, Pinder J, Martinez-Pastor B,
Theodorou M, Blackburn JS, Abraham BJ, Namiki Y, Mansour M,
Abdelfattah NS, Molodtsov A, et al: TOX regulates growth, DNA
repair, and genomic instability in T-cell acute lymphoblastic
leukemia. Cancer Discov. 7:1336–1353. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawabata S, Mercado-Matos JR, Hollander
MC, Donahue D, Wilson W III, Regales L, Butaney M, Pao W, Wong KK,
Jänne PA and Dennis PA: Rapamycin prevents the development and
progression of mutant epidermal growth factor receptor lung tumors
with the acquired resistance mutation T790M. Cell Rep. 7:1824–1832.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Farmery MR, Tjernberg LO, Pursglove SE,
Bergman A, Winblad B and Näslund J: Partial purification and
characterization of gamma-secretase from post-mortem human brain. J
Biol Chem. 278:24277–24284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW
and Mook-Jung I: ERK1/2 is an endogenous negative regulator of the
gamma-secretase activity. FASEB J. 20:157–159. 2006. View Article : Google Scholar
|
|
36
|
Kawabata S, Hollander MC, Munasinghe JP,
Brinster LR, Mercado-Matos JR, Li J, Regales L, Pao W, Jänne PA,
Wong KK, et al: Epidermal growth factor receptor as a novel
molecular target for aggressive papillary tumors in the middle ear
and temporal bone. Oncotarget. 6:11357–11368. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bachhawat AK and Kaur A: Glutathione
degradation. Antioxid Redox Signal. 27:1200–1216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chi Z, Byrne ST, Dolinko A, Harraz MM, Kim
MS, Umanah G, Zhong J, Chen R, Zhang J, Xu J, et al: Botch is a
γ-glutamyl cyclotransferase that deglycinates and antagonizes
Notch. Cell Rep. 7:681–688. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin YW, Nichols RA, Letterio JJ and Aplan
PD: Notch1 mutations are important for leukemic transformation in
murine models of precursor-T leukemia/lymphoma. Blood.
107:2540–2543. 2006. View Article : Google Scholar
|
|
40
|
Santos LO, Garcia-Gomes AS, Catanho M,
Sodre CL, Santos ALS, Branquinha MH and d'Avila-Levy CM: Aspartic
peptidases of human pathogenic trypanosomatids: Perspectives and
trends for chemotherapy. Curr Med Chem. 20:3116–3133. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gu Y, Wang X, Wang Y, Wang Y, Li J and Yu
FX: Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of
proteasome inhibitors. Cell Signal. 75:1097752020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
De Strooper B, Iwatsubo T and Wolfe MS:
Presenilins and γ-secretase: Structure, function, and role in
Alzheimer disease. Cold Spring Harb Perspect Med. 2:a0063042012.
View Article : Google Scholar
|
|
43
|
Li X, Dang S, Yan C, Gong X, Wang J and
Shi Y: Structure of a presenilin family intramembrane aspartate
protease. Nature. 493:56–61. 2013. View Article : Google Scholar
|
|
44
|
Fukumori A, Fluhrer R, Steiner H and Haass
C: Three-amino acid spacing of presenilin endoproteolysis suggests
a general stepwise cleavage of gamma-secretase-mediated
intramembrane proteolysis. J Neurosci. 30:7853–7862. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gertsik N, Ballard TE, Am Ende CW, Johnson
DS and Li YM: Development of CBAP-BPyne, a probe for γ-secretase
and presenilinase. Medchemcomm. 5:338–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sato T, Diehl TS, Narayanan S, Funamoto S,
Ihara Y, De Strooper B, Steiner H, Haass C and Wolfe MS: Active
gamma-secretase complexes contain only one of each component. J
Biol Chem. 282:33985–33993. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rand MD, Grimm LM, Artavanis-Tsakonas S,
Patriub V, Blacklow SC, Sklar J and Aster JC: Calcium depletion
dissociates and activates heterodimeric notch receptors. Mol Cell
Biol. 20:1825–1835. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Meckler X and Checler F: Presenilin 1 and
presenilin 2 target γ-secretase complexes to distinct cellular
compartments. J Biol Chem. 291:12821–12837. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Stanga S, Vrancx C, Tasiaux B, Marinangeli
C, Karlström H and Kienlen-Campard P: Specificity of presenilin-1-
and presenilin-2-dependent γ-secretases towards substrate
processing. J Cell Mol Med. 22:823–833. 2018. View Article : Google Scholar
|
|
50
|
Mungrue IN, Pagnon J, Kohannim O,
Gargalovic PS and Lusis AJ: CHAC1/MGC4504 is a novel proapoptotic
component of the unfolded protein response, downstream of the
ATF4-ATF3-CHOP cascade. J Immunol. 182:466–476. 2009. View Article : Google Scholar
|
|
51
|
Kumar A, Tikoo S, Maity S, Sengupta S,
Sengupta S, Kaur A and Bachhawat AK: Mammalian proapoptotic factor
ChaC1 and its homologues function as γ-glutamyl cyclotransferases
acting specifically on glutathione. EMBO Rep. 13:1095–1101. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chi Z, Zhang J, Tokunaga A, Harraz MM,
Byrne ST, Dolinko A, Xu J, Blackshaw S, Gaiano N, Dawson TM and
Dawson VL: Botch promotes neurogenesis by antagonizing Notch. Dev
Cell. 22:707–720. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sathe A, Chalaud G, Oppolzer I, Wong KY,
von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA and
Nawroth R: Parallel PI3K, AKT and mTOR inhibition is required to
control feedback loops that limit tumor therapy. PLoS One.
13:e01908542018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yang M, Lu Y, Piao W and Jin H: The
translational regulation in mTOR pathway. Biomolecules. 12:8022022.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Budanov AV, Shoshani T, Faerman A, Zelin
E, Kamer I, Kalinski H, Gorodin S, Fishman A, Chajut A, Einat P, et
al: Identification of a novel stress-responsive gene Hi95 involved
in regulation of cell viability. Oncogene. 21:6017–6031. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Velasco-Miguel S, Buckbinder L, Jean P,
Gelbert L, Talbott R, Laidlaw J, Seizinger B and Kley N: PA26, a
novel target of the p53 tumor suppressor and member of the GADD
family of DNA damage and growth arrest inducible genes. Oncogene.
18:127–137. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Peeters H, Debeer P, Bairoch A, Wilquet V,
Huysmans C, Parthoens E, Fryns JP, Gewillig M, Nakamura Y, Niikawa
N, et al: PA26 is a candidate gene for heterotaxia in humans:
Identification of a novel PA26-related gene family in human and
mouse. Hum Genet. 112:573–580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Saveljeva S, Cleary P, Mnich K, Ayo A,
Pakos-Zebrucka K, Patterson JB, Logue SE and Samali A: Endoplasmic
reticulum stress-mediated induction of SESTRIN 2 potentiates cell
survival. Oncotarget. 7:12254–12266. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lee JH, Cho US and Karin M: Sestrin
regulation of TORC1: Is sestrin a leucine sensor? Sci Signal.
9:re52016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Brüning A, Rahmeh M and Friese K:
Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated
sestrin-2 regulation. Mol Oncol. 7:1012–1018. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hales EC, Taub JW and Matherly LH: New
insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling
axis: Targeted therapy of γ-secretase inhibitor resistant T-cell
acute lymphoblastic leukemia. Cell Signal. 26:149–161. 2014.
View Article : Google Scholar
|
|
62
|
Shen W, Zhou Q, Peng C, Li J, Yuan Q, Zhu
H, Zhao M, Jiang X, Liu W and Ren C: FBXW7 and the hallmarks of
cancer: Underlying mechanisms and prospective strategies. Front
Oncol. 12:8800772022. View Article : Google Scholar : PubMed/NCBI
|
